Healthcare / Drug Manufacturers - Specialty & GenericHKSE
$2.35
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 23%
FCF escenarios
weak_data · normalized FCF $221.9M · quality 52.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
39/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$6.8B
P/E
14.7x
↓EV/EBITDA
8.1x
↓ROE
6.4%
↑Gross Margin
41.6%
↓Debt/Equity
0.55
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-13.5%
FCF CAGR
-1.7%
FCF margin
7.2%
FCF / Net income
0.64x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $4.17B · net income $470.6M · FCF $299.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $4.17B | $4.17B | $5.77B | $6.46B | $6.43B |
| Net Income | $470.6M | $470.6M | $1.06B | $1.32B | $1.12B |
| EBITDA | $1.12B | $1.12B | $1.86B | $2.11B | $1.86B |
| EPS | — | — | 0.36 | 0.44 | 0.38 |
| Gross Margin | 41.6% | 41.6% | 50.4% | 56.0% | 55.4% |
| Operating Margin | 14.0% | 14.0% | 23.3% | 25.2% | 22.0% |
| Net Margin | 11.3% | 11.3% | 18.4% | 20.4% | 17.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.55 | 0.55 | 0.50 | 0.49 | 0.52 |
| Current Ratio | 1.89 | 1.89 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $299.8M | $299.8M | $-49.4M | $221.9M | $315.6M |
| Returns | |||||
| ROE | 6.4% | 6.4% | 14.7% | 19.0% | 18.1% |
| Valuation | |||||
| P/E | 14.69 | 14.69 | 9.52 | 11.07 | 13.24 |
| EV/EBITDA | 8.15 | 8.15 | 6.70 | 7.73 | 8.83 |
| P/B | 0.94 | 0.94 | 1.40 | 2.11 | 2.39 |
| Growth & Yield | |||||
| Revenue Growth | -27.8% | -27.8% | -10.7% | 0.5% | — |
| EPS Growth | — | — | -19.1% | 17.7% | — |
| Dividend Yield | 2.5% | 2.5% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-17.8%
Start / end P/E
n/dx → n/dx
EPS bridge
0.36 → n/d
Residual
-20.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.